Do you want to read an article? Please log in or register.
Outcomes of cataract surgery in eyes with diabetic macular oedema: Data from the Fight Retinal Blindness! Registry
Macular Diseases
RECOMMENDED
Related content
RECOMMENDED
Macular Diseases
Changes in real-world treatment patterns for diabetic macular oedema from 2009-2019 and five-year outcomes: Data from the Fight Retinal Blindness! Registry
★ 1
Recommended by
Prof. Dr emer. Josef Flammer, Faculty Member
doi: 10.1111/ceo.13781.
Macular Diseases
Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry
Eye (Lond)
Bhandari S, Squirrell D, Nguyen V, Wang N, Wells JM, Tan T, Barnes R, Barry R, Barthelmes D, Gillies M
doi: 10.1038/s41433-021-01509-x
COMMENTED
Macular Diseases
Initial observation or treatment for diabetic macular oedema with good visual acuity: two-year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry
★ 2
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Acta Ophthalmol
Gabrielle PH, Nguyen V, Bhandari S, Mehta H, Viola F, Arnold J, Fraser-Bell S, Barthelmes D, Creuzot-Garcher C, Gillies M
doi: 10.1111/aos.14672
RECOMMENDED
Macular Diseases
Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry
★ 3
Recommended by
Prof. Dr Daniel Barthelmes, Faculty Member
★ 3
Recommended by
Prof. Dr Ke Yao, Faculty Member
Ophthalmology.
Bhandari S, Nguyen V, Fraser-Bell S, Mehta H, Viola F, Baudin F, Gabrielle PH, Creuzot-Garcher C, Gillies M, Barthelmes D
doi: 10.1016/j.ophtha.2019.11.018.
Retinal Diseases
Intraocular Pressure Changes and VEGF Inhibitor Use in Various Retinal Diseases: Long-Term Outcomes in Routine Clinical Practice: Data from the Fight Retinal Blindness! Registry
Ophthalmol Retina.
Gabrielle PH, Nguyen V, Wolff B, Essex R, Young S, Hunt A, Gemmy Cheung CM, Arnold JJ, Barthelmes D, Creuzot-Garcher C, Gillies M, Fight Retinal Blindness! Study Group.
doi: 10.1016/j.oret.2020.06.020.
Macular Diseases
Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry
Ophthalmology.
Bhandari S, Nguyen V, Arnold J, Young S, Banerjee G, Gillies M, Barthelmes D
doi: 10.1016/j.ophtha.2019.10.006.
ConjunctivitisFlammer SyndromeMacular DiseasesRetinal DiseasesCataracts
12-month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry
Acta Ophthalmol
Niedzwiecki M, Hunt A, Nguyen V, Mehta H, Creuzot-Garcher C, Gabrielle PH, Guillemin M, Fraser-Bell S, Arnold J, McAllister IL, Gillies M, Barthelmes D
doi: 10.1111/aos.15014
Macular DiseasesRetinal Diseases
Cataract Surgery Outcomes in Eyes With Primary Epiretinal Membrane
JAMA Ophthalmol.
Hardin JS, Gauldin DW, Soliman MK, Chu CJ, Yang YC, Sallam AB
COMMENTED
Macular DiseasesRetinal Diseases
Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry
★ 1
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Acta Ophthalmol
Gabrielle PH, Nguyen V, Creuzot-Garcher C, Miguel L, Alforja S, Sararols L, Casaroli-Marano RP, Zarranz-Ventura J, Gillies M, Arnold J, Barthelmes D
doi: 10.1111/aos.14893